Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Free Cash Flow (2017 - 2025)

VYNE Therapeutics' Free Cash Flow history spans 9 years, with the latest figure at -$10.8 million for Q2 2025.

  • For Q2 2025, Free Cash Flow fell 26.9% year-over-year to -$10.8 million; the TTM value through Dec 2025 reached -$31.2 million, up 8.05%, while the annual FY2025 figure was -$33.1 million, 2.83% up from the prior year.
  • Free Cash Flow reached -$10.8 million in Q2 2025 per VYNE's latest filing, up from -$11.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$4.8 million in Q4 2022 to a low of -$17.5 million in Q3 2021.
  • Average Free Cash Flow over 5 years is -$9.3 million, with a median of -$8.8 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: skyrocketed 75.98% in 2021, then crashed 74.65% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$10.0 million in 2021, then surged by 51.98% to -$4.8 million in 2022, then decreased by 6.78% to -$5.1 million in 2023, then tumbled by 74.65% to -$9.0 million in 2024, then fell by 19.97% to -$10.8 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Free Cash Flow are -$10.8 million (Q2 2025), -$11.5 million (Q1 2025), and -$9.0 million (Q4 2024).